2023
Launch of Gorax and Anfonax . Agreement with SINOVAC for Argentina and Peru.
2022
Launching of Ultraciclib, Rupovar – Agreement with Biocon and Dr Reddy’s – Agreement with EUSA Pharma for Qarziba and Silvant - Agreement with Nanox for Nanotechnology Line.
2021
Agreement with Recordati for Signifor, Signifor LAR – Expansion of Rare Diseases Line – Opening new subsidiaries: Uruguay, Paraguay.
2020
Agreement with Recordati for Ledaga – Launching of Funomid, Suprol.
2019
Agreement with Aqvida and Aigen – Opening new subsidiaries: Chile, Perú, Ecuador - Launching of Lenvatib, Idelib Ponatib, Binap - Agreement with Adienne for Tepadina.
2018
Agreement with Myriad Genetics for Endopredict – Launching of Neurosciences Line.
2017
Acuerdo con Amgen para LATAM por Mvasi, Kanjinti.
2016
Agreement with Amgen for Blincyto, Xgeva.
2014
Agreement with Amgen for Neupogen, Neulastim, Aranesp.
2013
Launching of Relotib – Agreement with Onyx/Amgen for Kyprolis
2012
Argentina’s launching of Bendavar
2007
Agreement with Celgene for Vidaza
2005
Opening of our Manufacturing Plant
2004
Agreement with Octapharma for Hemostasis Portfolio.
2003
Agreement with Cassará Lab for Biotechnological Line.
